Ann: Immuron Aims to Secure FDA Approval for IMM-124E, page-20

An interesting ann.

OK, firstly, if they get an IND what happens then? I would guess a Ph 1 trial would be somewhat superfluous. They’ve mentioned they have clinical data already-where do they hope that parachutes them into the process? Ph II or Ph III? What are the timelines and how much will it cost? I suspect they need to get the IND before they can answer those sorts of questions.

The $100m is an anchoring figure which makes me a little nervous as that’s the kind of language companies use when they’re going to raise.

Finally, the phrase “diseases where LPS is a factor” is a bit vague. Which diseases are they? I did a bit of googling and it made me go hmmmmmm.